DBVT — DBV Technologies S.A.

Nasdaq · Health Care · Biotechnology · CIK 1613780 ·
Last close
$13.73
Market Cap
$812.65M
52W High
$21.38
52W Low
$13.14
ADV30
301,882
Next earnings
2026-10-28
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs include celiac disease. In addition, the company develops Viaskin technology platform, a platform to potentially treat food allergy. It has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Châtillon, France.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Jun 2026 0 -50,600,000 -50,400,000 223,200,000 174,900,000 62,800,000
Mar 2026 0 -47,900,000 -47,600,000 266,400,000 229,200,000 58,500,000
Dec 2025 0 -45,048,000 -44,829,000 233,718,000 194,167,000 64,948,000
Sep 2025 0 -34,277,000 -33,164,000 110,495,000 69,837,000 57,641,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-168,983,000
Investing CF
$-1,869,000
Financing CF
$248,182,000
CapEx
$-1,296,000
Dividends Paid
Buybacks
$-159,000
EPS Diluted TTM
$-3.90
As of
2026-07-19

Balance + Analyst (yfinance extras)

Retained Earnings
$-270,300,000
Inventory
Receivables
$17,300,000
ST Investments
EBIT TTM
$-177,825,000
Pretax Income TTM
$-175,219,000
Interest Exp TTM
Analysts
6

Yahoo Snapshot (yfinance, live)

Total Revenue
$5,036,000
EBITDA
$-174,762,000
Free Cash Flow
$-104,847,504
Enterprise Value
$650,117,696
Total Cash
$174,900,000
Total Debt
$7,700,000
Shares Out
59,187,875
Trailing EPS
$-3.50
Book Value
$2.71
ROE
-142.7%
ROA
-60.6%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 0 -147,054,000 -146,947,000 233,718,000 64,948,000 -121,181,000
Dec 2024 0 -116,590,000 -113,918,000 65,658,000 38,271,000 -104,474,000
Dec 2023 0 -76,433,000 -72,726,000 182,986,000 42,799,000 -79,653,000
Dec 2022 0 -96,631,000 -96,274,000 246,518,000 52,065,000 -55,666,000

TTM Snapshot

Revenues TTM
$3,533,000
NetIncome TTM
$-49,852,000
OpCashFlow TTM
$0
Assets (Latest)
$65,658,000
Forward EPS
$-0.53

Peers — same industry

TickerNameMarket CapLastDaily %
SLDB Solid Biosciences Inc. $791.53M $8.04
ODTX Odyssey Therapeutics, Inc. $866.97M $18.05
SANA Sana Biotechnology, Inc. $882.18M $3.17
AURA Aura Biosciences, Inc. $725.09M $7.01
CADL Candel Therapeutics, Inc. $688.74M $9.40

News headlines (Yahoo Finance, 1h cache)

DBV Technologies Announces Sale of Approximately $50 Million of ADSs Through Its At-The-Market (ATM) Program on Nasdaq
2026-07-30 21:40 · Yahoo
European Equities Traded in US as ADRs Ease in Tuesday Trading
2026-07-28 15:04 · Yahoo
Food Allergy Market on the Rise: 5 Emerging Therapies to Watch | DelveInsight
2026-07-27 14:31 · Yahoo
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading
2026-07-24 15:06 · Yahoo
European Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading
2026-07-22 15:10 · Yahoo
European Equities Traded in the US as American Depositary Receipts Track Lower in Monday Trading
2026-07-20 15:13 · Yahoo
DBV Technologies Files At-The-Market (ATM) Prospectus for Up to $150 Million of Sales
2026-07-17 21:00 · Yahoo
European Equities Traded in the US as American Depositary Receipts Decline Friday
2026-07-17 14:57 · Yahoo
DBV Technologies Q2 Earnings Call Highlights
2026-07-16 23:03 · Yahoo
DBV Technologies Announces the Filing of its 2026 Half-Year Report ― Conditions for Accessing or Consulting the Report
2026-07-16 20:10 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.